|August 19, 2014|
|09:47 EDT||LCI||Lannett could see decreased digoxin sales, says Craig-Hallum|
Last week an article in the Journal of American College of Cardiology, or JACC, highlighted concerns regarding increased mortality for Digoxin users. Craig-Hallum said Digoxin is one of Lannett's top drugs and believes the study combined with the push-back on last year's price increase could lead to a decrease in Digoxin sales. Shares are Buy rated but the analyst is growing more cautions near-term.
News For LCI From The Last 14 Days
|August 26, 2015|
|08:44 EDT||LCI||Lannett steady execution offers compelling upside, says Susquehanna|
Susquehanna noted Lannett delivered solid Q2 results and outlook and believes its stock price is undervaluing the upside potential from new products and business development. The firm also sees the potential for multiple expansion if volume trends remain steady. Susquehanna reiterated its Positive rating but lowered its price target to $70 from $75 on Lannett shares.
|August 25, 2015|
|16:08 EDT||LCI||Lannett sees FY16 CapEx $60M-$70M|
Which includes $30M to continue the partial fit-out of company-owned buildings. Sees FY16 gross margin as a percentage of net sales of approximately 71%-73%; R&D expense in the range of $33M-$35M; SG&A expense ranging from $57M-$59M, which includes approximately $5M in acquisition-related expenses; The full year effective tax rate to be in the range of 34%-35%.
|16:06 EDT||LCI||Lannett sees FY16 revenue $425M-$435M, consensus $433.55M|
|16:05 EDT||LCI||Lannett reports Q4 EPS 91c, consensus 86c|
Reports Q4 revenue $99.3M, consensus $97.62M.
|August 18, 2015|
|07:59 EDT||LCI||Lannett subsidiary receives approval for Aripiprazole Oral Solution|
Subscribe for More Information